Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2017/09/009934
CTRI/2017/09/009934
Not yet recruiting
Phase 1

Phase I â??II Clinical Trial on Safety, Immunogenicity and probing efficacy of the Revived Recombinant Vaccine against Human Chorionic Gonadotropin (hCG) - R-βhCG

Indian Council of Medical Research0 sites0 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
Indian Council of Medical Research
Status
Not yet recruiting
Last Updated
4 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • •1\.Willing to participate in the trial and sign the consent form and audio visual recording.
  • •2\.Healthy married sexually active women (age group 22\-35\) who have completed their family with minimum two living children.
  • •3\.Has ovulatory cycles
  • •4\. Menstruating regularly
  • •5\.Not using any hormonal contraceptive since the last 6 months
  • •6\.Using non\-hormonal IUDs or willing to use non\-hormonal IUDs or who have already undergone sterilization.
  • •7\.Women after six months of delivery with regular menstrual cycles or six weeks after Medical Termination of Pregnancy (MTP) with return of regular menstrual cycle.
  • •8\.Resident of Delhi/NCR

Exclusion Criteria

  • •1\.Women who are pregnant or suspecting pregnancy
  • •2\.who are currently breast feeding
  • •3\.women having â??
  • •i)STD, Reproductive Tract Infection (RTI) and HIV, HCV, Hepatitis B, VDRL, HBsAg infection,
  • •ii)Gynaecological disorders
  • •iii)history of recurrent abortion
  • •iv)history of Joint pains
  • •v)secondary infertility
  • •vi)any type of suspected cancer
  • •vii)allergic to any drug or food, auto\-immune and endocrine disorders

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Phase 2
Phase II Clinical Trial of Safety, Immunogenicity, and Mucosal Immunotherapy of Recombinant Lactococcus lactis Expressing Human Papillomavirus Type 16 E6/E7 Oncoprotein Vaccine in Women having Cervical Intraepithelial Neoplasia (CIN)Genital Wart.Anogenital (venereal) wartsA63.0
IRCT20190504043464N2Iran University of Medical Sciences220
Active, not recruiting
Not Applicable
Phase I and IIa trial to assess the safety, immunogenicity and protective efficacy against sporozoite challenge of the candidate malaria vaccine pfLSA-3 vaccine. - LSA3-trialP. falciparum infection (malaria)
EUCTR2006-001743-66-NLINSTITUT PASTEUR, Biomedical Parasitology Unit
Unknown
Phase 2
HIVIS03
PACTR2009040001075080Swedish Institute for Infectious Disease Control (SMI)
Recruiting
Phase 1
A phase I trial to assess safety and immunogenicity of an HLAII-targeted DNA vaccine against influenza H7N9Influenza prophylaxisTherapeutic area: Diseases [C] - Virus Diseases [C02]
CTIS2022-500706-18-01Oslo University Hospital Hf30
Completed
Phase 1
Study to evaluate safety and possible adverse reactions, especially serious, with a vaccine for measles and rubella in healthy subjects.Measles and Rubella
RBR-9hckj4Bio-Manguinhos/Fiocruz/MS